Carboplatin before surgery for high-risk BRCA prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate adenocarcinoma confirmed by biopsy or surgery pathology
- Your prostate cancer is “high” or “very high” risk based on staging, grade group (4–5), or PSA level over 20
- You have a confirmed inherited BRCA1 or BRCA2 gene mutation from a reputable genetic test
- You must be at least 18 years old and able to do normal daily activities (performance status 0–2)
- Your blood counts and organ tests are strong enough (neutrophils, platelets, liver and kidney blood tests meet limits)
- Your cancer must be suitable for surgery, with no spread to distant organs on imaging
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a chemotherapy drug called carboplatin to standard hormone therapy can help men with prostate cancer that has spread and has either a BRCA gene change or neuroendocrine features. The goal is to see if this combination slows the cancer and improves outcomes.
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial tests a treatment approach for newly diagnosed, high-risk prostate cancer. You would receive a short course of internal radiation (high-dose-rate brachytherapy) before surgery to remove your prostate. The goal is to see if this combination is safe and works better than surgery alone.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.